
This is the author’s final accepted version.

There may be differences between this version and the published version. You are advised to consult the publisher’s version if you wish to cite from it.

http://eprints.gla.ac.uk/149670/

Deposited on: 11 October 2017

Enlighten – Research publications by members of the University of Glasgow
http://eprints.gla.ac.uk
Effect of general anaesthesia on functional outcome among patients with anterior circulation ischaemic stroke undergoing endovascular thrombectomy versus standard care: a meta-analysis of individual patient data from seven randomised controlled trials

Bruce C.V. Campbell\textsuperscript{1} PhD, Wim H. van Zwam\textsuperscript{2} MD, Professor Mayank Goyal\textsuperscript{3} MD, Bijoy K. Menon\textsuperscript{3} MD, Professor Diederik W.J. Dippel\textsuperscript{4} MD, Professor Andrew M. Demchuk\textsuperscript{3} MD, Professor Serge Bracard\textsuperscript{5} MD, Professor Philip White\textsuperscript{6} MD, Professor Antoni Dávalos\textsuperscript{7} MD, Professor Charles B.L.M. Majoie\textsuperscript{8} MD PhD, Professor Aad van der Lugt\textsuperscript{9} MD, Gary A. Ford\textsuperscript{10} FRCP, Natalia Pérez de la Ossa\textsuperscript{7} MD, Professor Michael Kelly\textsuperscript{11} MD PhD, Romain Bourcier\textsuperscript{12} MD PhD, Professor Geoffrey A. Donnan\textsuperscript{13} MD, Professor Yvo B.W.E.M. Roos\textsuperscript{14} MD PhD, Professor Oh Young Bang\textsuperscript{15} MD, Professor Raul G. Nogueira\textsuperscript{16} MD, Thomas G. Devlin\textsuperscript{17} MD, Lucie A van den Berg\textsuperscript{14} MD, Professor Frédéric Clarençon\textsuperscript{18} MD PhD, Paul Burns\textsuperscript{19} MB BCh, Professor Jeffrey Carpenter\textsuperscript{20} MD, Olvert A. Berkhemer\textsuperscript{4,8,9} MD PhD, Professor Dileep R. Yavagal\textsuperscript{21} MD, Vitor Mendes Pereira\textsuperscript{22} MD, Professor Xavier Ducrocq\textsuperscript{23} MD, Anand Dixit\textsuperscript{5} MD, Helena Quesada\textsuperscript{24} MD, Jonathan Epstein\textsuperscript{25} MD, Professor Stephen M. Davis\textsuperscript{1} MD, Professor Olav Jansen\textsuperscript{26} PhD, Marta Rubiera\textsuperscript{27} MD, Xabier Urra\textsuperscript{28} MD, Emilien Micard\textsuperscript{29} MSc, Hester F Lingsma\textsuperscript{30} PhD, Professor Olivier Naggara\textsuperscript{31} PhD, Scott Brown\textsuperscript{32} PhD, Professor Francis Guillemin\textsuperscript{25*} MD, Professor Keith W. Muir\textsuperscript{33*} PhD, Professor Robert J. van Oostenbrugge\textsuperscript{34*} MD, Professor Jeffrey L. Saver\textsuperscript{35*} MD, Professor Tudor G. Jovin\textsuperscript{36*} MD, Professor Michael D. Hill\textsuperscript{3*} MD, Professor Peter J. Mitchell\textsuperscript{37*} MMed for the HERMES collaborators
* have contributed equally.

1. Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia

2. Department of Radiology, Maastricht University Medical Center and Cardiovascular Research Institute (CARIM), Maastricht, the Netherlands

3. Department of Clinical Neurosciences, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Foothills Hospital, Calgary AB, Canada

4. Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.

5. Department of Diagnostic and Interventional Neuroradiology, INSERM U 947, University of Lorraine and University Hospital of Nancy, Nancy, France

6. Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK

7. Department of Neuroscience, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain

8. Department of Radiology, Academic Medical Center, Amsterdam, the Netherlands

9. Department of Radiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.

10. Division of Medical Sciences, University of Oxford and Oxford University Hospitals NHS Foundation Trust, Oxford, UK

11. Department of Medical Imaging, University of Saskatchewan, Saskatoon, Canada
12. Department of Neuroradiology, University and University Hospital of Nantes, Nantes, France

13. The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia

14. Department of Neurology, Academic Medical Center, Amsterdam, the Netherlands

15. Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

16. The Marcus Stroke and Neuroscience Center, Grady Memorial Hospital, Department of Neurology, Emory University School of Medicine, Atlanta, USA

17. Department of Neurology, University of Tennessee College of Medicine, Chattanooga, USA

18. Department of Neuroradiology, Pitié-Salpêtrière Hospital and Paris Pierre et Marie Curie University, Paris, France

19. Department of Neuroradiology, Royal Victoria Hospital, Belfast, Northern Ireland

20. Department of Radiology, West Virginia University Hospital, West Virginia, USA

21. Department of Neurology and Neurosurgery, University of Miami Miller School of Medicine–Jackson Memorial Hospital, Miami, USA

22. Division of Neuroradiology and Division of Neurosurgery, Departments of Medical Imaging and Surgery, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Canada

23. Department of Neurology, CHR Mercy, Metz, France
24. Stroke Unit, Hospital de Bellvitge, Barcelona, Spain

25. INSERM CIC-EC 1433 Clinical Epidemiology, University of Lorraine and University Hospital of Nancy, Nancy, France

26. Institute of Neuroradiology, Universitätsklinikum Kiel, Kiel, Germany

27. Stroke Unit, Hospital Vall d'Hebron, Barcelona, Spain

28. Stroke Unit, Hospital Clinic, Barcelona, Spain

29. CIC-IT INSERM 1433, University of Lorraine and University Hospital of Nancy, Nancy, France

30. Department of Public Health, Erasmus MC University Medical Center, Rotterdam, the Netherlands

31. Department of Neuroradiology, Sainte-Anne Hospital and Paris-Descartes University, INSERM U894, IMABRAIN, Neurosciences and Psychiatry Center, Paris, France

32. Altair Biostatistics, St Louis Park, Minnesota, USA

33. Institute of Neuroscience & Psychology, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, UK

34. Department of Neurology, Maastricht University Medical Center and Cardiovascular Research Institute (CARIM), Maastricht, the Netherlands

35. Department of Neurology and Comprehensive Stroke Center, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA

36. Stroke Institute, Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, USA

37. Department of Radiology, Royal Melbourne Hospital, University of Melbourne, Parkville, Australia
Cover Title: Effect of general anaesthesia in stroke thrombectomy

Abstract: 365 words

Manuscript text: 2891 words

Corresponding Author:
A/Prof Bruce Campbell, Department of Neurology, Royal Melbourne Hospital, Grattan St, Parkville Vic 3050, Australia
Tel: +61 3 9342 8448 Fax: +61 3 9342 8427
Email: bruce.campbell@mh.org.au
Abstract

**Background:** General anaesthesia (GA) during endovascular thrombectomy has been associated with worse patient outcomes in observational studies. We examined the association between GA and functional outcome in ischaemic stroke patients with large vessel anterior circulation occlusion undergoing endovascular thrombectomy versus standard care in pooled data from available trials.

**Methods:** Patient-level data were pooled from randomised trials listed in Pubmed 1/Jan/2010-31/May/2017 comparing endovascular thrombectomy performed using predominantly stent-retrievers with standard care in anterior circulation ischaemic stroke patients (HERMES Collaboration). The primary outcome was ordinal analysis of the modified Rankin scale (mRS) at 90 days in the GA and non-GA subgroups of endovascular-treated patients and patients randomised to standard care, adjusted for baseline prognostic variables. An alternative approach using propensity-score stratification was also used. To account for between-trial variance we used mixed-effects modeling with a random effect for trial incorporated in all models. Bias was assessed using the Cochrane tool.

**Findings:** Of 1764 patients in 7 trials, 871 were allocated to endovascular thrombectomy. After exclusion of 74 patients (72 who did not undergo the procedure and 2 with missing data on anaesthetic strategy), 236/797 (30%) of endovascular patients were treated under GA. At baseline, GA patients were younger and had shorter time to randomisation but similar pre-treatment clinical severity compared to non-GA. Endovascular thrombectomy improved functional outcome at 3 months versus standard care in both GA (adjusted
common odds ratio (cOR) 1·52, 95%CI 1·09-2·11, p=0·014) and non-GA
(adjusted cOR 2·33, 95%CI 1·75-3·10, p<0·001) patients. However,
outcomes were significantly better for those treated under non-GA versus GA
(covariate-adjusted cOR 1·53, 95%CI 1·14-2·04, p=0·004; propensity-
stratified cOR 1·44 95%CI 1·08-1·92, p=0·012). The risk of bias and variability
among studies was assessed to be low.

**Interpretation:** Worse outcomes after endovascular thrombectomy were
associated with GA, after adjustment for baseline prognostic variables. These
data support avoidance of GA whenever possible. The procedure did,
however, remain effective versus standard care in patients treated under GA,
indicating that treatment should not be withheld in those who require
anaesthesia for medical reasons.

**Funding:** The HERMES collaboration was funded by an unrestricted grant
from Medtronic to the University of Calgary.

---

**Research in context**

**Evidence before this study**

We searched Pubmed for studies examining the association of general
anaesthesia with outcome in stroke patients undergoing endovascular
thrombectomy between 1 Jan 2010 and 31 May 2017. Multiple observational
studies demonstrated worse outcome in patients treated under general
anaesthesia. Individual randomised trials of thrombectomy versus standard
care found conflicting results on the effect of general anaesthesia, varying
between abolition of the thrombectomy treatment effect in MR CLEAN and no
effect in THRACE. Three single-centre randomised trials of general
anaesthesia versus conscious sedation found either no difference in functional outcome between groups or a slight benefit of general anaesthesia.

**Added value of this study**

These data from contemporary, high quality randomised trials form the largest study to date of the association between general anesthesia and the benefit of endovascular thrombectomy versus standard care. We used two different approaches to adjust for baseline imbalances (multivariable logistic regression and propensity-score stratification). We found that GA for endovascular thrombectomy, as practiced in contemporary clinical care across a wide range of expert centres during the randomised trials, was associated with worse outcome than avoiding GA, independent of patient co-morbidities. Patients still benefited from thrombectomy compared to standard care when treated under GA.

**Implications of all the available evidence**

The requirement for GA due to airway compromise or agitation that threatens the quality of revascularization should not deter clinicians from pursuing endovascular thrombectomy. The contrast between this analysis and the recent randomised trials comparing GA and conscious sedation suggests that, when GA is medically necessary, close attention should be paid to minimizing anaesthetic delays to commence the procedure and maintaining physiological parameters such as blood pressure. A multi-centre randomised trial to definitively address these issues is warranted.
Introduction:

Multiple observational studies have suggested that patients treated with endovascular thrombectomy under general anaesthesia (GA) have poorer outcomes than those treated without GA.\textsuperscript{1} However, patients with more severe stroke or comorbidities may be more likely to be treated under GA, leading to the potential for confounding by indication. In MR CLEAN, sites specified their anaesthetic strategy prospectively and analysis of that trial found that the beneficial treatment effect of thrombectomy became non-significant in patients treated under GA.\textsuperscript{2} These results could lead to a reluctance to convert from an awake procedure to GA in cases where patient agitation or challenging vascular anatomy are preventing optimal revascularization. In contrast, three small single-centre randomised trials which compared GA, performed using strict protocols to maintain blood pressure, with conscious sedation using the same agents at lower doses without intubation did not detect a signal of harm and functional independence was either no different or slightly increased in the GA patients.\textsuperscript{3-5} We analysed the pooled individual patient data from available randomised trials to assess whether a treatment benefit was preserved in patients treated under GA in broader contemporary practice.
**Methods:**

We searched Pubmed for randomised trials published between 1 Jan 2010 and 31 May 2017 comparing endovascular thrombectomy performed using predominantly stent-retrievers with standard care in anterior circulation ischaemic stroke patients - Pubmed search string: ("randomized controlled trial"[Publication Type]) AND ((thrombectomy[Title/Abstract]) OR (clot retrieval[Title/Abstract]) OR intraarterial[Title/Abstract]) AND (stroke[Title/Abstract]) AND ("2010/01/01"[Date - Publication] : "2017/05/31"[Date - Publication])). The Highly Effective Reperfusion using Multiple Endovascular Devices (HERMES) collaboration pooled individual patient data from the MR CLEAN, ESCAPE, EXTEND-IA, SWIFT PRIME, REVASCAT, PISTE and THRACE trials. All participants provided informed consent according to each trial protocol and each study was approved by the local ethics board.

This meta-analysis was prospectively designed by the HERMES executive committee but not registered. The study protocol is included in the supplementary webappendix. Data were contributed by the authors of all the trials meeting eligibility criteria and collated by independent statisticians. All data relevant to the analyses presented were part of each study’s individual design and data collection and are part of the general HERMES database. No standardization or translation of the fields employed for analysis and reporting was necessary. After collation of data, key fields were compared to original results, including published data. No major discrepancies were found.
and minor discrepancies were resolved in collaboration with the study authors/investigators. The study selection process is outlined in supplementary Figure SA1. Variability between studies is described in supplementary Table SA1 and heterogeneity assessed in supplementary figures SA2-4. Risk of bias in the individual studies was assessed using the Cochrane handbook methodology\textsuperscript{14} and was low for all studies except THRACE which used unblinded assessment of day 90 functional outcome (supplementary Table SA2). The principal risk of bias derived from differences among individual studies’ methods and inclusion criteria. A one-stage approach was employed, defined as use of individual patient data with analysis including covariates and random study effects to appropriately incorporate any between-study differences.

In MR CLEAN, the steering committee gave no recommendations about anaesthetic management. Nevertheless, the majority of centres adhered to a fixed protocol regarding type of anesthetic management throughout the trial. In the other trials, the use of anaesthesia was at the discretion of the treating team on a case by case basis, although two trials (ESCAPE and REVASCAT) discouraged GA where possible.

Patients treated under GA (sedation with intubation) were identified and their baseline characteristics compared to the non-GA patients who were managed with or without sedation and not intubated.
The primary outcome was the mRS at 3 months, which was analysed using ordinal logistic regression to obtain the common odds ratio (cOR). Secondary outcomes were the proportion of patients reaching independence (mRS 0-2) and return to all usual activities (mRS 0-1) and the proportion with early neurological recovery defined as a ≥8 point reduction in National Institutes of Health Stroke Scale (NIHSS) or reaching 0-1 at 24 hours. Safety outcomes were the proportion of patients who had died at 90 days, the proportion with symptomatic intracerebral haemorrhage (SICH, as defined by each trial) and the proportion with parenchymal haematoma (PH, intracerebral blood clot with mass effect). The proportions of endovascular patients with vessel perforation and pneumonia were compared between GA and non-GA groups.

Regression analyses were adjusted for baseline prognostic factors including age, sex, NIHSS at baseline, ASPECTS, location of occlusion, treatment with intravenous alteplase (yes/no) and time to randomisation. Treatment was included as a variable with three levels: defined as GA, non-GA and controls. To account for between-trial variance we used mixed-effects modeling with a random effect for trial incorporated in all models. In addition, as a sensitivity analysis, propensity scores were constructed using logistic regression with GA vs no GA as the outcome and employing the same set of baseline variables as in the regression models. Propensities were then incorporated into the outcome model for the ordinal modified Rankin scale (mRS) score by stratification into five groups.15
Role of the funding source

An unrestricted grant was provided to the University of Calgary by Medtronic who had no role in study design, the collection, analysis or interpretation of data, the writing of the report or the decision to submit the paper for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results:

In the pooled data of 1764 patients, 871 were randomised to endovascular thrombectomy and 893 to standard medical care. After exclusion of 74 patients (72 who did not undergo the procedure and 2 with missing data on anaesthetic strategy), 236/797 (30%) of endovascular patients were treated under GA. At baseline, patients treated under GA were younger and had shorter time from stroke onset to randomisation than those treated without GA (Table 1). Baseline clinical severity (NIHSS) was not significantly different between groups. GA was used in 113/394 (29%) of right hemisphere and 119/392 (30%) of left hemisphere stroke patients (p=0.64). GA patients were more likely to receive alteplase and had a lower rate of diabetes mellitus.

Functional and neurological outcome

At 3 months, the patients who underwent endovascular treatment had significantly greater odds of improved functional outcome versus standard medical care in covariate-adjusted analysis in both GA (common odds ratio [cOR] 1.52 CI95 1.09-2.11, p=0.014) and non-GA (cOR 2.33 CI95 1.75-3.10,
p<0·001) groups, Table 2, Figure 1. There was no heterogeneity in the effect of GA on outcome among studies, although the small numbers limit power for this analysis. The odds of improved outcome using non-GA versus GA were significantly greater in ordinal analysis of the mRS, after adjustment for baseline prognostic factors (cOR 1·53 CI95 1·14-2·04, p=0·004). For every 100 patients treated under GA versus no GA, 18 patients would have worse functional outcome, including 10 who would not achieve functional independence. The propensity-stratified analysis generated similar results and the common odds ratio for improved outcome for non-GA vs GA was 1·44, CI95 1·08-1·92, p=0·012. Secondary outcomes followed similar trends (Table 2).

Safety
The rate of SICH did not differ between endovascular patients treated under GA, those treated without GA or standard medical care patients. The 90-day mortality was 13.4% in non-GA patients versus 17.3% in standard medical care (p=0·07) and 17.4% in GA patients (Table 2). Pneumonia occurred in a similar proportion of GA versus non-GA patients (11·4% versus 8·4% p=0·18), although the reported incidence of pneumonia was significantly different among studies (p<0·001), likely indicating differences in definition or in capture of adverse events. Vessel perforation occurred in 0.4% GA versus 1.6% non-GA patients (p=0·30).
Procedural characteristics and time metrics

The proportion of patients with successful reperfusion post-procedure (modified Treatment in Cerebral Infarction mTICI 2b/3 i.e. reperfusion of greater than 50% of the affected territory) did not differ between GA and no GA patients (75.1% vs 76.1%, p=0.78). The time interval between randomisation and reperfusion was significantly greater in GA versus non-GA patients (median 105 vs 85 min, p<0.001). However, there was an imbalance in the time from stroke onset to randomisation which was median 5 minutes shorter in the GA group (p=0.04) and the difference in total onset to reperfusion time between both groups was therefore not significant (median 302 vs 288 min, p=0.57, Table 1).

Discussion

Patients treated under GA suffered poorer outcomes compared to those treated without GA, after adjustment for baseline characteristics. The magnitude of this effect was clinically significant – for every 100 patients treated under GA versus no GA, 18 patients would have worse functional outcome, including 10 who would not achieve functional independence. However, a significant benefit of endovascular thrombectomy over standard care was retained in those patients treated under GA.
The randomised trials differed in their proportion of patients treated under GA but the experience in REVASCAT and ESCAPE, which discouraged GA, was that <10% of anterior circulation stroke patients had an absolute requirement for GA. MR CLEAN has previously reported that GA was associated with marked attenuation of treatment effect.\textsuperscript{2} It is possible that the lower rate of revascularization in MR CLEAN attenuated the potential treatment benefit compared to EXTEND-IA and SWIFT PRIME. However, the THRACE trial reported no difference in outcomes in patients treated with or without GA despite a similar effect size to MR CLEAN.\textsuperscript{13}

The method of GA in these randomised trials was entirely at the discretion of the treating team and there were no formal protocols specifying anaesthetic agents, blood pressure targets or other aspects of physiological management. This is in contrast to the highly protocol-specified approach to both GA and conscious sedation in the SIESTA, ANSTROKE and GOLIATH trials.\textsuperscript{3-5} In particular, strict attention to maintaining systolic blood pressure >140mmHg throughout the procedure (including during anaesthetic induction) may have been critical to preserving collateral blood flow to the ischaemic penumbra and preventing a harmful effect of GA. There were also specified criteria to prevent hyper or hypoventilation.

Each of the GA vs conscious sedation randomised trials also used the same medications in both treatment arms, the difference being lower dose and absence of intubation in the conscious sedation group. This contrasts with the HERMES non-GA patient group, in which treatment varied between no
sedative medication at all and use of sedatives and anaesthetic agents but without intubation. The use of local anaesthetic agent at the arterial puncture site without any sedative agent, which is routine at many institutions, may have different implications for patient outcome compared to conscious sedation as described in the recent randomised trials. Different anaesthetic agents could also vary in their protective or harmful effects on ischaemic brain, among other hypothetical differences between approaches.\(^\text{16}\) The details of the medications given in the HERMES patients were not available for this analysis.

Although the main reasons given for using GA are procedural safety and securing the airway, there was no significant difference in the rate of vessel perforation or pneumonia between GA and non-GA patients. Our data therefore do not support GA as a safer approach to treatment and demonstrate the general technical safety of endovascular thrombectomy. There are potential advantages of avoiding GA, including the ability to assess neurological status during the procedure, reduced intensive care requirements post-procedure and reduced costs. In the HERMES trials, GA was also associated with a delay in reperfusion. However, this was not the case in the randomised trials where a slight delay to start the procedure in GA patients (on average <10 minutes) appeared to be offset by shorter procedural time. This may be plausible if reduced patient movement allows more efficient roadmap techniques. However, the three centres that performed the randomised trials of GA achieved exceptionally fast anaesthetic induction that may not be common practice at most institutions.
The main limitation of this study is that the choice to use GA versus non-GA was not randomised and the differentiation between medically required GA versus elective GA was not recorded in the trial databases. The important prognostic variables of age and time from stroke onset to randomisation favoured the GA group. We used two different methods of adjustment for baseline imbalances (multivariate regression and propensity-score stratification) which gave consistent results. Nonetheless, for both methods the possibility of unmeasured confounding remains. The anaesthetic practices in the HERMES trials were not pre-specified by protocol nor recorded in detail but are likely to have been substantially more variable than the recent single centre randomised trials comparing GA versus no GA. However, this also represents a strength of our study as results are likely to be generalizable to current clinical practice. The risk of bias in component trials was overall assessed to be low.

In conclusion, the HERMES data suggest that GA for endovascular thrombectomy, as practiced in contemporary clinical care across a wide range of expert centres during the randomised trials, is associated with worse outcome compared to avoiding GA, independent of patient co-morbidities. Patients still benefited from thrombectomy compared to standard care when treated under GA. Therefore, the requirement for GA due to airway compromise or agitation that threatens the quality of revascularization should not deter clinicians from pursuing endovascular thrombectomy. The contrast between the HERMES data and the recent randomised trials comparing GA
and conscious sedation suggests that, when GA is medically necessary, close attention should be paid to minimizing anaesthetic delays to commence the procedure and maintaining physiological parameters such as blood pressure. A multi-centre randomised trial to definitively address these issues is warranted.

Acknowledgment

nil

Contributors

BCVC prepared the first draft of the report based on an analysis plan agreed by the HERMES Executive (BCVC, MG, DWJD, AMD, S Bracard, PW, AD, CBLM, FG, KWM, JLS, TJG, MDH, PJM) who also contributed to study interpretation. SB performed the statistical analyses. All authors participated in patient enrolment, data collection, critically reviewed the report and approved the final version. FG, KWM, RJvO, JLS, TGJ, MDH and PJM contributed equally.
Declaration of interests

B.C.V. Campbell: reports research support from the National Health and Medical Research Council of Australia (GNT1043242, GNT1035688, GNT1113352), Royal Australasian College of Physicians, Royal Melbourne Hospital Foundation, National Heart Foundation, National Stroke Foundation of Australia and unrestricted grant funding for the EXTEND-IA trial to the Florey Institute of Neuroscience and Mental Health from Covidien (Medtronic).

W.H. van Zwam reports speaker’s honoraria from Stryker and Cerenovus (paid to institution).

M. Goyal reports grants and personal fees from Medtronic and Stryker. He has a patent (US 9486176 B2) Systems and methods for diagnosing strokes licensed to GE Healthcare and a patent (US 20160022964 A1) Systems of intracranial access licensed to Microvention.

B. Menon: reports membership of the Steering and Executive Committee, ESCAPE trial that received support from Medtronic, Site Principal Investigator, SOCRATES Trial, sponsored by Astra Zeneca, speakers honoraria from Penumbra Inc., a provisional patent 62/086077 for triaging systems in ischaemic stroke, research funding from Canadian Institutes of Health Research (CIHR), Heart and Stroke Foundation of Canada (HSFC), Alberta Innovates - Health Solutions (AIHS), Hotchkiss Brain Institute (HBI) and the Faculty of Medicine, University of Calgary.

D. Dippel reports grants from Dutch Heart Foundation, AngioCare BV, Medtronic/Covidien/EV3®, MEDAC Gmbh/LAMEPRO, Penumbra Inc., Top Medical/Concentric, Stryker and his institution received consultancy fees from Stryker, Bracco Imaging and Servier.
A. Demchuk reports personal fees from Covidien (Medtronic).

S. Bracard: Has nothing to disclose.

P. White reports grants from National Institutes for Health Research, Stroke Association, Medtronic (Covidien) and Codman and has consulted for Microvention Terumo and Codman.

A. Dávalos reports lecture fees, consultancy and advisory board fees from Medtronic Neurovascular (Steering Committee STAR) and unrestricted grant for the REVASCAT trial from Medtronic (paid to institution).

C.B.L. Majoie reports an unrestricted grant from Stryker (paid to institution).

A.V.D. Lugt reports honoraria from Stryker (paid to institution).

G.A. Ford reports grants and personal fees from Medtronic, personal fees from Pfizer, Athersys, AstraZeneca, Lundbeck, Cerevast, Daiichi Sankyo personal fees and non-financial support from Boehringer Ingelheim, grants from Pulse Therapeutics.

N. Perez de la Ossa: Has nothing to disclose.

M. Kelly reports grants from the University of Calgary.

R Bourcier: Has nothing to disclose.

G. Donnan: Has nothing to disclose.

Y.B.W.E.M. Roos: Has nothing to disclose.

O.Y. Bang: Has nothing to disclose.

R. Noguiera reports travel support from Stryker for activities related to the DAWN trial.

T. Devlin: Has nothing to disclose.

L.A. van den Berg: Has nothing to disclose.
F. Clarençon reports acting as a consultant for Medtronic, and personal fees from Balt (paid lectures) and Codman Neurovascular (study core lab).

P. Burns: Has nothing to disclose.

J. Carpenter: Has nothing to disclose.

O.A. Berkhemer reports honoraria from Stryker (paid to institution).

D. Yavagal reports consulting for Medtronic Neurovascular as a Steering Committee Member for the SWIFT PRIME trial.

V. Pereira reports personal fees from Medtronic.

X. Ducrocq: Has nothing to disclose.

A. Dixit: Has nothing to disclose.

H. Quesada: Has nothing to disclose.

J. Epstein: Has nothing to disclose.

S. Davis reports lecture fees from Covidien (Medtronic) and personal fees for advisory board membership for Boehringer Ingelheim.

O. Jansen: Has nothing to disclose

M. Rubiera: Has nothing to disclose

X. Urra: Has nothing to disclose

E. Micard: Has nothing to disclose

H. Lingsma: Has nothing to disclose

O. Naggara: Has nothing to disclose

S. Brown reports statistical consulting fees from the University of Calgary and personal fees as a consultant for Medtronic.

F. Guillemin: Has nothing to disclose

K.W. Muir has received personal fees as a consultant for Medtronic and Boehringer Ingelheim. The University of Glasgow received grant support for
the PISTE trial from Medtronic and Codman as well grants from the Stroke Association (TSA 2011/06) and the National Institute of Health Research (NIHR) Health Technology Assessment programme (HTA 14.08.47).

R.J. van Oostenbrugge: Has nothing to disclose

J. Saver has acted as a scientific consultant regarding trial design and conduct to Medtronic.

T.G. Jovin: has received personal fees as a consultant for Codman Neurovascular and Neuravi, holds stock in Silk Road, Anaconda, Route 92 and Blockade; received travel expenses from Stryker as PI of the DAWN trial and from Fundacio Ictus related to the REVASCAT and RACECAT trials.

M. Hill reports unrestricted grant funding for the ESCAPE trial and HERMES collaboration to University of Calgary from Covidien (Medtronic), and grants from the Heart & Stroke Foundation, Canadian Institutes of Health Research, Alberta Innovates Health Solutions, Alberta Health Services and grant and in-kind support from the University of Calgary (Hotchkiss Brain Institute, Departments of Clinical Neurosciences and Radiology, and Calgary Stroke Program). He is a director of the Canadian Federation of Neurological Sciences, and has received personal fees from Merck, non-financial support from Hoffmann-La Roche Canada Ltd, has a patent Systems and Methods for Assisting in Decision-Making and Triaging for Acute Stroke Patients pending to US Patent office Number: 62/086,077 and owns stock in Calgary Scientific Incorporated, a company that focuses on medical imaging software.

P.J. Mitchell reports unrestricted grant funding for the EXTEND-IA trial to the Florey Institute of Neuroscience and Mental Health from Covidien (Medtronic), has served as an unpaid consultant to Codman Johnson and Johnson, his
organization has received unrestricted research funding and grants from Codman Johnson and Johnson, Medtronic, and Stryker.

References


Figure 1 – Distribution of modified Rankin Scale at 3 months in patients treated under general anaesthesia versus without general anaesthesia (no GA) versus the standard medical care group.
Table 1 – Baseline characteristics of endovascular patients treated under general anaesthesia (GA) versus without GA (no GA) and those who received standard care.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>GA (n=236)</th>
<th>No GA (n=561)</th>
<th>p-value GA vs no GA</th>
<th>All Endovascular (n=871)</th>
<th>All Standard Care (n=893)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD)</td>
<td>63.8 (14)</td>
<td>66.3 (13.3)</td>
<td>0.015</td>
<td>65.5 (13.5)</td>
<td>65.7 (13.5)</td>
</tr>
<tr>
<td>Female sex % (n)</td>
<td>42.8% (101/236)</td>
<td>48.7% (273/561)</td>
<td>0.14</td>
<td>47.3% (412/871)</td>
<td>47.3% (421/891)</td>
</tr>
<tr>
<td>NIHSS at baseline, median (IQR)</td>
<td>18 (15-21)</td>
<td>17 (14-20)</td>
<td>0.09</td>
<td>17 (14-20)</td>
<td>17 (13-21)</td>
</tr>
<tr>
<td>ASPECTS, median (IQR)</td>
<td>7 (6-8)</td>
<td>8 (7-9)</td>
<td>0.0005</td>
<td>8 (7-9)</td>
<td>8 (7-9)</td>
</tr>
<tr>
<td>Left hemisphere affected % (n)</td>
<td>51.3% (119/232)</td>
<td>49.3% (273/554)</td>
<td>0.64</td>
<td>49.5% (424/856)</td>
<td>50.2% (442/881)</td>
</tr>
<tr>
<td>Directly admitted to treating centre % (n)</td>
<td>75.4% (178/236)</td>
<td>77.3% (432/559)</td>
<td>0.57</td>
<td>78.0% (678/869)</td>
<td>75.2% (668/888)</td>
</tr>
<tr>
<td>Onset to randomisation, min median (IQR)</td>
<td>179 (137-238)</td>
<td>184 (144-246)</td>
<td>0.04</td>
<td>181 (141-241)</td>
<td>184 (140-250)</td>
</tr>
<tr>
<td>Randomisation to reperfusion, min, median (IQR)</td>
<td>105 (80-149)</td>
<td>85 (51-118)</td>
<td>&lt;0.0001</td>
<td>92 (61-128)</td>
<td>NA</td>
</tr>
<tr>
<td>Onset to reperfusion, min median (IQR)</td>
<td>302 (246-357)</td>
<td>288 (222-358)</td>
<td>0.57</td>
<td>291 (231,357)</td>
<td>NA</td>
</tr>
<tr>
<td>Site of arterial occlusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICA occlusion % (n)</td>
<td>25.0% (59/236)</td>
<td>25.7% (144/561)</td>
<td>0.13</td>
<td>24.7% (215/871)</td>
<td>25.4% (227/893)</td>
</tr>
<tr>
<td>M1 occlusion % (n)</td>
<td>59.7% (141/236)</td>
<td>61.1% (343/561)</td>
<td></td>
<td>61.5% (536/871)</td>
<td>60.1% (537/893)</td>
</tr>
<tr>
<td>M2 occlusion % (n)</td>
<td>6.4% (15/236)</td>
<td>8.4% (47/561)</td>
<td></td>
<td>7.7% (67/871)</td>
<td>7.2% (64/893)</td>
</tr>
<tr>
<td>Unknown % (n)</td>
<td>8.9% (21/236)</td>
<td>4.8% (27/561)</td>
<td></td>
<td>6.1% (53/871)</td>
<td>7.2% (64/893)</td>
</tr>
<tr>
<td>Alteplase administered % (n)</td>
<td>92.4% (218/236)</td>
<td>84.3% (473/561)</td>
<td>0.002</td>
<td>87.6% (763/871)</td>
<td>90.6% (809/893)</td>
</tr>
<tr>
<td>Hypertension % (n)</td>
<td>50.9% (119/234)</td>
<td>56.1% (315/561)</td>
<td>0.18</td>
<td>53.6% (465/867)</td>
<td>58.8% (523/890)</td>
</tr>
<tr>
<td>Hyperlipidemia % (n)</td>
<td>29.7% (69/232)</td>
<td>36.9% (202/548)</td>
<td>0.06</td>
<td>35.5% (300/846)</td>
<td>40.2% (351/873)</td>
</tr>
<tr>
<td>Diabetes mellitus % (n)</td>
<td>8.9% (21/236)</td>
<td>18.2% (102/560)</td>
<td>0.0009</td>
<td>15.1% (131/867)</td>
<td>17.5% (156/889)</td>
</tr>
<tr>
<td>Smoking % (n)</td>
<td>39.0% (85/218)</td>
<td>36.3% (183/504)</td>
<td>0.503</td>
<td>37.8% (298/788)</td>
<td>36.6% (300/820)</td>
</tr>
</tbody>
</table>

SD standard deviation, IQR interquartile range, NIHSS National Institutes of Health Stroke Scale (standardized neurological examination) ranges from normal (0) to death (42). ASPECTS Alberta Stroke Program Early Computed Tomography Score (reflects extent of early ischaemic change on CT brain: 10 is normal, 0 is involvement of the entire middle cerebral artery territory). ICA internal carotid artery, M1 first segment of middle cerebral artery (pre-bifurcation), M2 second segment of middle cerebral artery (from bifurcation to the circular sulcus of the insula in the Sylvian fissure).
### Table 2 – Outcomes in patients treated with standard care versus endovascular thrombectomy with or without general anaesthesia (GA)

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Standard Care (n=893)</th>
<th>Thrombectomy with GA (n=236)</th>
<th>Thrombectomy without GA (n=561)</th>
<th>GA vs Standard *</th>
<th>No GA vs Standard *</th>
<th>No GA vs GA *</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Effect size OR (95%CI)</td>
<td>P value</td>
<td>Effect size OR (95%CI)</td>
</tr>
<tr>
<td><strong>Primary outcome</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Functional outcome at 90 days (modified Rankin Scale – mRS) Ordinal analysis† – median (IQR) – <strong>covariate adjusted common odds ratio</strong></td>
<td>4 (2, 5)</td>
<td>3 (2, 4)</td>
<td>2 (1, 4)</td>
<td>1·52 (1·09-2·11)</td>
<td>0·01</td>
<td>2·33 (1·75-3·10)</td>
</tr>
<tr>
<td>– propensity-score stratification common odds ratio</td>
<td>1·42 (1·09-1·84)</td>
<td>0·008</td>
<td>2·21 (1·65-2·95)</td>
<td>&lt;0·0001</td>
<td>1·44 (1·08-1·92)</td>
<td>0·01</td>
</tr>
<tr>
<td><strong>Secondary Outcomes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Independent functional outcome (mRS0–2)</td>
<td>30·6%</td>
<td>40·2%</td>
<td>50·3%</td>
<td>1·62 (1·16-2·26)</td>
<td>0·005</td>
<td>2·72 (1·99-3·72)</td>
</tr>
<tr>
<td>Excellent functional outcome (mRS0–1)</td>
<td>16·6%</td>
<td>22·6%</td>
<td>31·6%</td>
<td>1·53 (1·02-2·31)</td>
<td>0·04</td>
<td>2·72 (2·00-3·69)</td>
</tr>
<tr>
<td>Early neurological improvement (NIHSS reduction ≥8 points or reaching 0–1 at 24h)†</td>
<td>23·8%</td>
<td>38·1%</td>
<td>53·2%</td>
<td>2·02 (1·36-3·00)</td>
<td>0·0005</td>
<td>3·92 (2·73-5·62)</td>
</tr>
<tr>
<td><strong>Safety</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death within 90 days</td>
<td>17·3%</td>
<td>17·4%</td>
<td>13·4%</td>
<td>1·01 (0·67-1·52)</td>
<td>0·96</td>
<td>0·73 (0·52-1·02)</td>
</tr>
<tr>
<td>Symptomatic intracerebral haemorrhage‡</td>
<td>3·5%</td>
<td>4·4%</td>
<td>3·8%</td>
<td>1·19 (0·56-2·51)</td>
<td>0·65</td>
<td>1·14 (0·62-2·10)</td>
</tr>
<tr>
<td>Parenchymal haematoma (PH)</td>
<td>10·2%</td>
<td>14·3%</td>
<td>11·4%</td>
<td>1·38 (0·86-2·22)</td>
<td>0·19</td>
<td>1·25 (0·72-2·16)</td>
</tr>
</tbody>
</table>

OR odds ratio, CI confidence interval, IQR interquartile range

* adjusted for age, sex, baseline stroke severity, site of occlusion, intravenous alteplase treatment, ASPECTS score, and time from onset to randomisation

† Modified Rankin scale (mRS) ranges from normal (0) to death (6). Analysis combined mRS 5 & 6

‡ National Institutes of Health Stroke Scale (NIHSS) score (standardized neurological examination) ranges from normal (0) to death (42), 8 point reduction is highly clinically significant.

§ SICH - Symptomatic intracerebral haemorrhage defined by source trial.